## **Product Information**

## Sunitinib Malate

Item No. 13159

Sold for research purposes under agreement from Pfizer Inc.

CAS Registry No.: 341031-54-7

N-[2-(diethylamino)ethyl]-5-[(Z)-(5-Formal Name:

> fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1Hpyrrole-3-carboxamide,(2S)-hydroxy-

Butanedioic acid

Synonyms: Sutent™, SU 11248

MF:  $C_{22}H_{27}FN_4O_2 \cdot C_4H_6O_5$ 

FW: 532.6 **Purity:** ≥98%

Stability: ≥2 years at -20°C Supplied as: A crystalline solid

# СООН HOOC

## **Laboratory Procedures**

For long term storage, we suggest that sunitinib malate be stored as supplied at -20°C. It should be stable for at least two years.

Sunitinib malate is supplied as a crystalline solid. A stock solution may be made by dissolving the sunitinib malate in an organic solvent purged with an inert gas. Sunitinib malate is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of sunitinib malate in DMSO is approximately 5 mg/ml and approximately 1 mg/ml in

Sunitinib malate is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, sunitinib malate should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Sunitinib malate has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Sunitinib malate is a small molecule, multi-targeted receptor tyrosine kinase inhibitor. It potently inhibits signaling through PDGFR, VEGFR, KIT, and FLT3.1 Through these effects, sunitinib malate inhibits both tumor cell growth and angiogenesis, leading to reduced tumor vascularization and cancer cell death.<sup>2,3</sup> It has been approved by the FDA for the treatment of gastrointestinal stromal tumors and metastatic renal cell carcinoma.

### References

- 1. O'Farrell, A.-M., Abrams, T.J., Yuen, H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101, 3597-3605 (2003).
- 2. Mendel, D.B., Laird, A.D., Xin, X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327-337 (2003).
- 3. Motzer, R.J., Michaelson, M.D., Redman, B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).

### Related Products

For a list of related products please visit: www.caymanchem.com/catalog/13159

WARNING: This product is for laboratory research only: not for administration to humans. Not for human or veterinary DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

## WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes **no warranty or guarantee** of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular pose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications

ayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for of direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence.

This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees.

Buyer's exclusive remedy and Cayman's sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman's option, the replacement, at no cost to Buyer, of all material that

Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within try (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog.

Copyright Cayman Chemical Company, 10/31/2013

## **Cayman Chemical**

### **Mailing address**

1180 E. Ellsworth Road Ann Arbor, MI 48108 USA

## **Phone**

(800) 364-9897 (734) 971-3335

(734) 971-3640

custserv@caymanchem.com

www.caymanchem.com